快速訂購

BAFF/BLyS/TNFSF13B  Protein, Antibody, ELISA Kit, cDNA Clone

描述: Active  
表達宿主: Human Cells  
  • Slide 1
10056-H01H-5
10056-H01H-20
10056-H01H-100
5 µg 
20 µg 
100 µg 
Add to Cart
表達宿主: E. coli  
  • Slide 1
10056-HNAE-50
10056-HNAE-20
50 µg 
20 µg 
Add to Cart
描述: Active  
表達宿主: Human Cells  
  • Slide 1
10056-HNCH-500
10056-HNCH-5
10056-HNCH-20
10056-HNCH-100
10056-HNCH-1
500 µg 
5 µg 
20 µg 
100 µg 
1 mg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
90267-C01H-50
90267-C01H-20
90267-C01H-100
50 µg 
20 µg 
100 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
70112-D01H-50
70112-D01H-20
50 µg 
20 µg 
Add to Cart

BAFF/BLyS/TNFSF13B 相关研究领域

BAFF/BLyS/TNFSF13B 相關信號通路

BAFF/BLyS/TNFSF13B 相關蛋白、抗體、cDNA基因、ELISA試劑盒

BAFF/BLyS/TNFSF13B 概述&蛋白信息

BAFF/BLyS/TNFSF13B 研究背景

基因概述: The protein encoded by TNFSF13B gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Mar 2011]
General information above from NCBI
亞單位結構: Homotrimer. Isoform 2 heteromultimerizes with isoform 1, probably limiting the amount of functional isoform 1 on the cell surface. Isoform 3 is unlikely form trimers or bind to BAFF receptors. {ECO:0000269|PubMed:12867412, ECO:0000269|PubMed:22749832}.
亞細胞定位: Cell membrane; Single-pass type II membrane protein.; Tumor necrosis factor ligand superfamily member 13b, soluble form: Secreted.
組織特異性: Abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. Also found in the spleen, lymph node, bone marrow, T-cells and dendritic cells. A lower expression seen in placenta, heart, lung, fetal liver, thymus, and pancreas. Isoform 2 is expressed in many myeloid cell lines. {ECO:0000269|PubMed:12867412}.
誘導: Up-regulated by exposure to IFNG/IFN-gamma. Down-regulated by phorbol myristate acetate/ionomycin treatment.
翻譯後修飾: The soluble form derives from the membrane form by proteolytic processing.; Isoform 2 is not efficiently shed from the membrane unlike isoform 1. {ECO:0000250}.; N-glycosylated.
相似的序列: Belongs to the tumor necrosis factor family. {ECO:0000305}.
General information above from UniProt

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

BAFF/BLyS/TNFSF13B 別稱

BAFF/BLyS/TNFSF13B 相關文獻

  • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
  • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
  • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.
  • 請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”